As soon as EGFR-TKIs became available, a series of clinical trials, such as INTACT 1[5], INTACT 2[6], TALENT[7], and TRIBUTE[8], were conducted to investigate the effect of chemotherapy alone or in combination with TKIs in non-selected patients with advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.